{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=14&q=DLBCL", "query": { "q": "DLBCL", "condition": "Lymphoma", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 477, "total_pages": 48, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=15&q=DLBCL&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=13&q=DLBCL&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T23:02:23.231Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04830137", "title": "A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia (CLL)", "Small Lymphocytic Lymphoma (SLL)", "Waldenstrom Macroglobulinemia (WM)", "Mantle Cell Lymphoma (MCL)", "Marginal Zone Lymphoma (MZL)", "Follicular Lymphoma (FL)", "Diffuse Large B-cell Lymphoma (DLBCL)", "Primary Central Nervous System Lymphoma (PCNSL)" ], "interventions": [ { "name": "NX-2127", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nurix Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 248, "start_date": "2021-05-05", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-03-20", "last_synced_at": "2026-10-13T23:02:23.231Z", "location_count": 16, "location_summary": "Duarte, California • Orange, California • San Francisco, California + 13 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Miami Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04830137" }, { "nct_id": "NCT03298412", "title": "Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High-risk Diffuse Large B-cell Lymphoma" ], "interventions": [ { "name": "Blinatumomab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 10, "start_date": "2018-05-23", "completion_date": "2019-09-30", "has_results": true, "last_update_posted_date": "2020-09-11", "last_synced_at": "2026-10-13T23:02:23.231Z", "location_count": 4, "location_summary": "Atlanta, Georgia • Maywood, Illinois • Cleveland, Ohio + 1 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03298412" }, { "nct_id": "NCT02446457", "title": "Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3a Follicular Lymphoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2015-07-31", "completion_date": "2026-04-30", "has_results": true, "last_update_posted_date": "2026-03-09", "last_synced_at": "2026-10-13T23:02:23.231Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02446457" }, { "nct_id": "NCT05207670", "title": "A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Mosunetuzumab (Cohorts A-C)", "type": "DRUG" }, { "name": "Mosunetuzumab (Cohorts D-E)", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 320, "start_date": "2022-02-01", "completion_date": "2027-07-31", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-10-13T23:02:23.231Z", "location_count": 39, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 34 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05207670" }, { "nct_id": "NCT03064867", "title": "Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Large B-cell-lymphoma" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Molly Gallogly", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2017-06-26", "completion_date": "2023-08-12", "has_results": false, "last_update_posted_date": "2022-11-16", "last_synced_at": "2026-10-13T23:02:23.231Z", "location_count": 3, "location_summary": "St Louis, Missouri • Cleveland, Ohio", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03064867" }, { "nct_id": "NCT03743246", "title": "A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Precursor Cell Lymphoblastic Leukemia-Lymphoma", "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "JCAR017", "type": "DRUG" }, { "name": "Lymphodepleting", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "25 Years", "sex": "ALL", "summary": "Up to 25 Years" }, "enrollment_count": 21, "start_date": "2018-10-17", "completion_date": "2024-01-26", "has_results": true, "last_update_posted_date": "2024-08-15", "last_synced_at": "2026-10-13T23:02:23.231Z", "location_count": 9, "location_summary": "Duarte, California • Redwood City, California • St. Petersburg, Florida + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Redwood City", "state": "California" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03743246" }, { "nct_id": "NCT04442022", "title": "A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Relapsed/Refractory Diffuse Large B-cell Lymphoma" ], "interventions": [ { "name": "Selinexor (combination therapy)", "type": "DRUG" }, { "name": "Placebo matching for Selinexor (combination therapy)", "type": "DRUG" }, { "name": "Rituximab (combination therapy)", "type": "DRUG" }, { "name": "Gemcitabine (combination therapy)", "type": "DRUG" }, { "name": "Dexamethasone (combination therapy)", "type": "DRUG" }, { "name": "Cisplatin (combination therapy)", "type": "DRUG" }, { "name": "Selinexor (continuous therapy)", "type": "DRUG" }, { "name": "Placebo matching for Selinexor (continuous therapy)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Karyopharm Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 501, "start_date": "2020-09-03", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-13T23:02:23.231Z", "location_count": 8, "location_summary": "Chandler, Arizona • Tucson, Arizona • Cerritos, California + 4 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Cerritos", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04442022" }, { "nct_id": "NCT00776802", "title": "GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Large B-cell Lymphoma" ], "interventions": [ { "name": "GCS-100", "type": "DRUG" }, { "name": "Etoposide; Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "La Jolla Pharmaceutical Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2008-07", "completion_date": "2009-04", "has_results": false, "last_update_posted_date": "2013-06-25", "last_synced_at": "2026-10-13T23:02:23.231Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00776802" }, { "nct_id": "NCT01607892", "title": "Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematological Malignancies" ], "interventions": [ { "name": "KPT-330", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Karyopharm Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 286, "start_date": "2012-07-23", "completion_date": "2015-10-13", "has_results": true, "last_update_posted_date": "2023-01-26", "last_synced_at": "2026-10-13T23:02:23.231Z", "location_count": 9, "location_summary": "Tampa, Florida • Boston, Massachusetts • St Louis, Missouri + 6 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01607892" }, { "nct_id": "NCT01421667", "title": "A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, B-Cell", "Lymphoma, Large B-Cell, Diffuse", "Lymphoma, Non-Hodgkin", "Lymphoma, T-Cell" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" }, { "name": "rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": null, "sex": "ALL", "summary": "6 Years and older" }, "enrollment_count": 176, "start_date": "2011-08", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2016-11-28", "last_synced_at": "2026-10-13T23:02:23.231Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Duarte, California • Oxnard, California + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Oxnard", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01421667" } ] }